Management of chronic hepatitis B

Hatef Massoumi1, Paul Martin, Hui-Hui Tan

  • 1Division of Gastroenterology and Hepatology, Albert Einstein College of Medicine, Bronx, New York, USA.

Insights

Chronic hepatitis B is a significant global health issue. Treatment aims to prevent severe liver disease, cancer, and death, with timely referral for transplant evaluation crucial for advanced cases.

Area of Science:

  • Hepatology
  • Virology
  • Public Health

Background:

  • Chronic hepatitis B (CHB) represents a substantial global health burden, impacting healthcare resources and finances.
  • CHB infection can lead to severe liver conditions, including cirrhosis and hepatocellular carcinoma.
  • Disease progression is influenced by host and viral factors, necessitating individualized treatment strategies.

Purpose of the Study:

  • To summarize the current understanding of chronic hepatitis B.
  • To outline the goals of hepatitis B treatment.
  • To emphasize the importance of timely management for patients with advanced disease.

Main Methods:

  • Review of existing literature on chronic hepatitis B natural history and treatment.
  • Analysis of factors influencing disease progression and treatment outcomes.
  • Guidelines for patient management, including referral criteria.

Main Results:

  • The natural history of chronic hepatitis B varies based on acquisition timing and host/viral factors.
  • Current treatments aim to halt disease progression, prevent complications like liver failure and cancer, and reduce mortality.
  • Early identification and management are key to improving patient outcomes.

Conclusions:

  • Effective management of chronic hepatitis B is essential to mitigate its global health impact.
  • Treatment goals focus on preventing long-term complications and improving survival.
  • Patients with decompensated cirrhosis require prompt referral to specialized liver transplant centers.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...